Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Conversion of paid subscribed units (BTU) into shares and warrants

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, SOUTH AFRICA, CANADA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.   Brighter AB (publ) (“Brighter” or the “Company”) has completed a rights issue of units of maximum approximately SEK 117 million (the “Rights Issue”). The Rights Issue was subscribed to a total of 85.4 percent. A total of 166,666,667 units were issued in the Rights Issue, corresponding to 333,333,334 shares, 333,333,

Nomination Committee proposal for Board of Directors of Diös Fastigheter AB (publ)

Prior to the Annual General Meeting of Diös Fastigheter AB (publ) on April 5, 2022, the Nomination Committee hereby announces its proposal regarding the Chairman of the Board and other Board members.The Nomination Committee propose: · re-election of Bob Persson, Ragnhild Backman, Anders Nelson, Peter Strand and Tobias Lönnevall. Eva Nygren has declined re-election, · to elect Erika Olsén as a new Board member · to elect Bob Persson as Chairman of the Board Erika Olsén was born in 1976 and holds a MSc in Real Estate and Economics from the Royal Institute of

BioStock: CombiGene’s CEO gives business development update

CombiGene’s pilot study, which is aimed at optimising the administration of the drug candidate CG01, has given the company valuable insights for future development steps. The path towards clinical studies, which will take place with support from partner Spark Therapeutics, thus takes another step forward. BioStock contacted the company’s CEO Jan Nilsson who talks about the collaboration with Spark, and how the company views its intensified investment in business development.Read the full interview with Jan Nilsson at biostock.se: https://www.biostock.se/en/2022/02/combigenes-ceo-gives-

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release February 11, 2022 at 9:45 a.m. Nokian Tyres has received an announcement from BlackRock, Inc. on February 10, 2022, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement BlackRock, Inc.'s total holding in Nokian Tyres shares exceeded the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on February 9, 2022. BlackRock, Inc. and its funds held on deal date a total of 6,954,281 Nokian Tyres’ shares representing 5.00% of the company’s 138,921,750

BioStock: Respiratorius raises 45 MSEK and prepares COPD project spinoff

Lund-based Respiratorius has announced carrying out a fully guaranteed rights issue to raise 45 MSEK. A majority of the capital will be allocated to finance the continued development of the COPD project RCD405, as the company eyes spinning off the project. Another large part of the funds will go towards preparing for an upcoming phase III study with VAL001 for the treatement of diffuse large-cell B-cell lymphoma, as the company gears up for selling the project.Read the full article at biostock.se:https://www.biostock.se/en/2022/02/respiratorius-raises-45-msek-and-prepares-copd-project-

Prevas Year-End Report 2021

Prevas reaches all-time highs.Proposed dividend 3.50 SEK/share (2.0) October - December 2021 · Net turnover 319.9 MSEK (202.7) · Operating profit/loss EBIT 42.4 MSEK (15.5) · Operating margin EBIT 13.2 % (7.6) · Profit after tax 37.8 MSEK (13.4) · Profit per share 3.05 SEK (1.32) January - December 2021 · Net turnover 1 186.9 MSEK (771.7) · Operating profit/loss EBIT 133.2 MSEK (65.6) · Operating margin EBIT 11.1 % (8.5) · Profit after tax 102.8 MSEK (45.2) · Profit per share 8.08 SEK (4.55) A word from the CEO Strong development. Record upon

Year-end report 1 January – 31 December 2021

As a result of the eased restrictions, all operations were able to re-open in what for the Group is the very important fourth quarter. All venues, productions and activity restaurants were able to run their operations to the fullest during the period with the exception of Oslo and Copenhagen, which were forced to close a few weeks before the Christmas break.FOURTH QUARTER 2021 2021 2020 2021 2020SEK million Oct–Dec Oct–Dec Jan–Dec Jan–DecNet sales 259 49 396

Year-end Report 1 October – 31 December 2021

· Despite pandemic related challenges: 30% sales growth and surgeries in 15 countries during 2021 · Episurf Medical’s first 510(k) submission completed in line with timetable. FDA review ongoing · Commercial organisation expanded with Head of Sales OUS, re-start of commercial activities following the end of the pandemic”Approaching the end of the pandemic is a relief on a human level, far beyond business life. However, it is fair to say that wearing the Episurf jersey during the pandemic has been extremely tough. Elective surgery has been severely hit, with experimental elective

Continued strong sales growth and improvement in operating income

PowerCell Sweden AB grew its sales by 49 percent during the fourth quarter 2021, from MSEK 38.2 to MSEK 56.8 compared with the same quarter last year. For the full year 2021, sales grew by 54 percent to MSEK 159.8 (103.5). Operating income improved to MSEK -23.9 (-29.5) due to continued increasing sales and strengthened gross margin.The fourth quarter 2021 was yet another very strong quarter for PowerCell Sweden AB with a new sales record for a single quarter. Sales for the full year also set a record. “Demand continued to be strong during the quarter with large-scale deliveries to

Implantica conducts innovative eHealth workshop

Implantica AG (publ), an emerging and fast growing med-tech company that is pioneering innovative solutions to treat chronic health conditions with smart implants, announces the successful completion of a 3-day eHealth workshop to advance the usability of our unique eHealth platform technology.Twenty experts from all over Europe participated in this intensive seminar. The sessions provided a more comprehensive understanding of the use cases throughout the life cycle of stages of the implant from manufacture to the different treatment stages until end-of-treatment. “Implantica’s expert

Nordea Bank Abp: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act (BlackRock, Inc.)

Nordea Bank AbpStock exchange release – Major shareholder announcements11 February 2022 at 9.30 EET Nordea Bank Abp has on 10 February 2022 received a notification under Chapter 9, Section 5 of the Securities Markets Act, according to which BlackRock, Inc.'s indirect shareholding of Nordea Bank Abp’s shares and voting rights has decreased below the threshold of 5 per cent on 9 February 2022. The total number of shares and voting rights in Nordea Bank Abp is 3,930,834,811. Total positions of BlackRock, Inc. and its funds according to the notification: +----------------+-------

Skanska completes groundwork for railway station in Bergen, Norway, for NOK 384M, about SEK 400M

Skanska has signed a contract with Baneservice for the completion of groundwork in the Fløen railway station project in Bergen, Norway. The contract is worth NOK 384M, about SEK 400M, which will be included in the Nordic order bookings for the first quarter 2022.Skanska will be responsible for all excavation work, handling of masses, construction of ditches, preparation of ground, water and drainage systems, and sorting of masses and asphalt. The works are part of the railway project Nygårdstangen–Bergen–Fløen, which Baneservice is carrying out for BaneNOR. Construction start is May 2022,

YEAR-END REPORT 2021

2021 FISCAL YEAR · Rental revenue increased 7% to SEK 3,100 M (SEK 2,898 in the year-earlier period). · Profit from property management increased 17% to SEK 2,805 M (2,389). · Profit from property management per Class A and B share after dilution rose 21% to SEK 7.99 (6.62). · In total, property revaluation affected profit by SEK 6,336 M (2,003). · Revaluation of financial instruments had an impact on profit of SEK 1,966 M (210). · Profit after tax for the year amounted to SEK 9,807 M (3,711), corresponding to SEK 30.04 (10.78) per Class A and B share after dilution. ·

Year-end report 2021

NET ASSET VALUE AND THE LATOUR SHARE · The net asset value rose to SEK 216 per share, compared with SEK 153 per share at the start of the year. This is an increase of 43.4 per cent, adjusted for dividends. By comparison, the Stockholm Stock Exchange's Total Return Index (SIXRX) increased by 39.3 per cent. The net asset value was SEK 190 per share at 10 February.[1 ] · The total return on the Latour share was 86.8 per cent during the period measured against the SIXRX, which rose 39.3 per cent. · The Board of Directors proposes an increased dividend of SEK 3.30 (3.00) per share.

Year-end Report 2021 – Pricer AB (publ)

Stable net sales development in the fourth quarter and new record-high sales and order intake for full-year 2021Fourth quarter 2021 · Net sales amounted to SEK 487.9 M (680.3), a decrease of 28 percent compared to the same period last year. · Operating profit amounted to SEK 17.2 M (69.3), which corresponds to an operating margin of 3.5 percent (10.2). · Order intake was SEK 453 M (454), unchanged compared to the same period last year. · Order backlog amounted to SEK 383 M (495), of which the majority is expected to be delivered in the first half of 2022. · Profit for the

Aker Solutions Secures Maintenance and Modifications Work for Equinor

February 11, 2022 – Aker Solutions has signed a three-year contract extension to an existing maintenance and modifications frame agreement with Equinor. The agreement for work on oil and gas installations offshore Norway represents a very large[1] order intake for Aker Solutions.Maintenance and modifications are crucial to ensure safe and efficient operations of customer’s installations and facilities. Aker Solutions has delivered maintenance and modifications work for Equinor on this frame agreement since first-quarter 2016. Work under the extension option will start upon completion of the

Raute Corporation - Financial statements release January 1-December 31, 2021

RAUTE CORPORATION FINANCIAL STATEMENTS RELEASE FEBRUARY 11, 2022 AT 9:05 A.M.   RAUTE CORPORATION – FINANCIAL STATEMENTS RELEASE JANUARY 1 – DECEMBER 31, 2021   This is a summary of Raute’s Financial statements release January 1 – December 31, 2021. The full report is a PDF file attachment to this stock exchange release and is also available on the company's website at www.raute.com.   - The Group’s net sales amounted to EUR 142.2 million (MEUR 115.0), up 24% on the comparison year. Order intake, at EUR 203 million (MEUR 119), was at a record level and increased by 71%.

Vitec presents new financial goal and ambitions for sustainability

The Board has decided to update the Group's financial goals and ambitions for sustainability work. Objective and business concept have also been adjusted.“Our new goals are in line with our strategy for long-term and sustainable profitability. Increasing our focus on sustainability strengthens our business concept. Our greatest opportunity to influence is through our products and how we act as a company and our ambition is to integrate sustainability throughout the value chain to continue to deliver on our brand promise, To rely on – today and tomorrow,” says Olle Backman, CEO Vitec

Kemira Oyj: Notice to the Annual General Meeting

Kemira Oyj, Stock Exchange Release, February 11, 2022 at 9.00 am (EET)Kemira Oyj: Notice to the Annual General Meeting Notice is given to the shareholders of Kemira Oyj (“Kemira” or the “company”) to the Annual General Meeting to be held on Thursday, March 24, 2022 at 1.00 p.m. EET at Flik, Studio Stage, Itämerentori 2, 00180, Helsinki, Finland. The shareholders and their proxy representatives may participate in the meeting and exercise their rights as shareholders only by voting in advance and/or by submitting counterproposals and/or questions in advance. Instructions can be found in

Biotage AB (publ) Year-end report January – December 2021

Strong growth, both organic and acquired   October–December  · Net sales amounted to SEK 341 (298) million, an increase of 14.5 percent and an organic* growth of 10.0 percent. · The operating profit amounted to SEK 61 (60) million, and adjusted to SEK 70 (60) million. · The operating margin was 18.0 percent (20.0), and adjusted was 20.7 percent (20.0). · EBITA* amounted to SEK 67 (62) million, and adjusted to SEK 76 (62) million. · EBITA margin* was 19.5 percent (20.9) and adjusted was 22.2 percent (20.9). · Profit after tax amounted to SEK 46 (44) million.  ·

Year-end report January-December 2021

· Profit from property management attributable to parent company shareholders amounted to SEK 5,543m (4,244), corresponding to an increase per share by 26 % to SEK 29.72 (23.51)  · Long term net asset value amounted to SEK 503.76 per share (387.38)  · Rental income amounted to SEK 8,956m (8,134)  · Profit after tax attributable to parent company shareholders amounted to SEK 18,508m (6,641) corresponding to SEK 99.24 per share (36.79) Profit from property management for the year amounted to SEK 6,129m (4,900). Profit from property management attributable to parent company

Alligator Bioscience AB: Year End report January–December 2021

OPTIMIZE-1 Phase II – On Track and Moving Forward “During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical, clinical, and partnered programs. Our priorities continue to be shaped by the rising need for cancer drug therapies that are safer and more effective.” Søren BregenholtCEO Alligator Bioscience AB (publ) Significant Events: October – December 2021 · First patient dosed in the Phase II clinical trial of AC101 (HLX22), out-licensed to Shanghai Henlius Biotech, Inc. and AbClon, Inc. · Proof-of-concept Phase I clinical trial was

EAB Group Plc’s financial statements bulletin 2021: The Group’s operating income increased by 19%, and the result for the period of EUR 2.1 million was the Group’s best ever

EAB Group Plc, Stock Exchange Release, 11 February 2022, 9:00 a.m. (EET) EAB Group Plc’s financial statements bulletin 2021: The Group’s operating income increased by 19%, and the result for the period of EUR 2.1 million was the Group’s best ever Operating income of the EAB Group (hereinafter “EAB” or “the Group”) for the period 1 January–31 December 2021 was EUR 22.2 million (EUR 18.7 million in 2020), and the result for the period was EUR 2.1 million (EUR 0.3 million in 2020). The Group’s operating result was EUR 2.9 million (EUR 0.6 million in 2020). Operating income included EUR

Vitec Software Group AB Year-end report January - December 2021

Summary of interim period, January–December 2021• Net sales SEK 1,571 million (1,313), an increase of 20%• Recurring revenues SEK 1,324 million (1,080), an increase of 23% including 7% organic• EBITA was SEK 440 million (345), with an EBITA margin of 28% (26)• Operating profit was SEK 283 million (222), with an operating margin of 18% (17)• Earnings per share before dilution SEK 6.14 (4.93)• Cash flow from operating activities SEK 488 million (436)• The Board of Directors propose increased dividend of SEK 2.00 per share (1.64)Summary of interim period, October–December 2021

There are no items matching the current filter
There are no more items matching the current filter
Back to top